Jfl Life Sciences share price
NSE: JFLLIFEPharmaceuticals & Biotechnology
Jfl Life Sciences Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2022 · Issue price ₹61
Last close ₹10.00down ₹0.25 (2.44%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹10.25.
28 Oct: open ₹10.00, high ₹10.00, low ₹10.00
52-week range of traded prices to 28 Oct 2026
₹8.55Low, 30 Mar 2026₹15.40High, 24 Dec 2025
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹33 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 4.87
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.72
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.47
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,000100.0% delivered
Results
Standalone; ₹ crore.Jfl Life Sciences quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹11 Crdown 82.39%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹1.11 Crdown 32.86%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 10.0%
Revenue by quarter
Peak revenue ₹63 Cr, quarter to Mar 2026; lowest ₹11 Cr, quarter to Jun 2026
Net profit by quarter, a loss in red
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 21.3 | 11.7 | 11.6 | 29.9 | 26.8 | 63.1 | 11.1 |
| Net profit | 0.7 | 0.1 | 0.7 | 2.0 | 2.0 | 1.7 | 1.1 |
| Net margin | 3.5% | 0.7% | 6.4% | 6.6% | 7.5% | 2.6% | 10.0% |
Standalone. The 7 quarters from Dec 2024, the first on record; the half years before them are below. The latest is shaded.
| ₹ crore | Sep 2024 |
|---|---|
| Revenue | 49.1 |
| Net profit | 3.3 |
| Net margin | 6.8% |
Standalone. The half years in the same span that the quarters on record do not fully cover.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹131 Crup 60.14%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹6.40 Crup 54.05%
- Net margin
- 4.9%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2024, the company's revenue for that year, ₹47 Cr, differs from its quarters added, ₹48 Cr.
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 43 | 47 | 82 | 131 |
| Net profit | 3 | 4 | 4 | 6 |
| Net margin | 6.6% | 7.5% | 5.1% | 4.9% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICALS, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2024: days before it are of the company before the change.Jfl Life Sciences PE ratio and valuation
Price to earnings
At or below today's level on 11% of 186 trading days over the last year.
LowestHighest
Its median6.36Industry median28.20
Price to book
At or below today's level on 23% of 186 trading days over the last year.
LowestHighest
Its median0.78Industry median2.99
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 71% of 576 trading days over the last 3 years.
LowestHighest
Its median0.00%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −51.0% | −48.6% | −4.6% | 0.0% |
| 3 years | −7.8% | – | – | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Jfl Life Sciences competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Jfl Life Sciences in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Chandra Bhagat PharmaCBPL | 36 | 12.60 | 1.07 | +34.1% | +229.5% | 9.0% | – | 0.00% |
 Sandu PharmaceuticalsSANDUPHQ | 36 | 20.09 | 0.81 | +4.2% | +10.3% | 4.1% | 5.3% | 2.72% |
 Rajnish WellnessRAJNISH | 36 | – | 0.35 | +356.9% | – | – | −8.2% | 0.00% |
 Roopa IndustriesROOPAIND | 34 | 261.57 | 1.90 | +3.7% | −93.7% | 0.7% | 15.4% | 0.00% |
 Gujarat Terce LaboratoriesGUJTERC | 33 | 15.59 | 3.35 | −7.2% | – | 25.8% | 25.8% | 0.00% |
 Medi CapsMEDICAPQ | 31 | – | 0.28 | −42.9% | – | −1.5% | −8.7% | 0.00% |
 Goldline PharmaceuticalGLPL | 29 | 7.11 | 2.05 | – | – | 28.9% | – | 0.00% |
 Sunrest LifescienceSUNREST | 29 | 6.98 | – | – | – | 22.4% | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Jfl Life Sciences dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹0.08 a share, year to Mar 2024.
| Ex-date | Type | Per share |
|---|---|---|
| 13 Sep 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.25 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Jfl Life Sciences announcements
Oct 2026
22 Oct · Board meeting
Aug 2026
26 Aug
25 Aug · Meeting
10 Aug · Results
Jfl Life Sciences share price by year
Each calendar year to 2025.Jfl Life Sciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 12.50 | −59.3% | 29.25 | 11.25 |
| 2024 | 30.75 | +122.3% | 35.40 | 12.35 |
| 2023 | 13.83 | +22.1% | 17.83 | 10.83 |
| 2022 | 11.33 | – | 22.17 | 10.67 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 16 Jan 2025. 2022 is from its first session, 8 Sep 2022.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 9.85 | 10.25 | 9.85 | 10.25 | 10.05 | 12,000 | 100.0% |
| 22 Oct 2026 | 10.30 | 10.30 | 10.30 | 10.30 | 10.30 | 6,000 | 100.0% |
| 21 Oct 2026 | 9.85 | 10.80 | 9.85 | 10.80 | 10.32 | 12,000 | 50.0% |
| 19 Oct 2026 | 10.35 | 10.35 | 10.35 | 10.35 | 10.35 | 6,000 | 100.0% |
| 16 Oct 2026 | 11.10 | 11.35 | 10.35 | 10.85 | 10.76 | 36,000 | 50.0% |
| 15 Oct 2026 | 10.75 | 10.85 | 10.75 | 10.85 | 10.80 | 12,000 | 100.0% |
| 14 Oct 2026 | 10.95 | 10.95 | 10.75 | 10.75 | 10.85 | 12,000 | 100.0% |
| 13 Oct 2026 | 10.75 | 10.75 | 10.70 | 10.75 | 10.73 | 18,000 | 100.0% |
| 7 Oct 2026 | 10.20 | 10.25 | 10.20 | 10.25 | 10.22 | 12,000 | 100.0% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 10 Mar 2026 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 24 Sep 2024 | Bonus | 0.3333 | Holders received 2 bonus shares for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- NSE symbol
- JFLLIFE
- ISIN
- INE0LA901015
- Industry
- Pharmaceuticals & Biotechnology